Where the category stands in May 2026 — what's available, who to trust, what costs what. 22-min read, medically reviewed.
Read the guideAn independent overview of the compounded-GLP-1 telehealth market and the providers we cover — market size, what the FDA changed, and an honest read on each.
View the provider overviewOverview & reviewsPrimers for newcomers and deep dives for the curious. The foundation articles are published; more are in the pipeline.
View all Learn articlesWhat compounded and branded semaglutide and tirzepatide actually cost, from each provider's own published pricing.
A Texas dual 503A/503B compounder covering HRT, aesthetics, and weight management (including sublingual semaglutide), shipping nationwide.
This profile is editorial. PeptideWellness has no commercial relationship with this pharmacy; coverage and assessment are never for sale.
Carie Boyd’s runs both a 503B outsourcing facility (office-use batches) and a patient-specific 503A pharmacy — one of the more established dual-status compounders squarely in the consumer wellness space (hormones, aesthetics, weight loss).
The 503B facility (legal entity “Right Value Drug Stores, LLC,” Irving, TX) is on the FDA Registered Outsourcing Facilities list [1], and the company also operates a 503A patient-specific pharmacy in Denton, TX [2]. It says it ships nationwide with free 2-day shipping [2]. On accreditation, a search of ACHC’s PCAB directory did not return a listing for Carie Boyd’s [3]; the company doesn’t prominently claim PCAB, so treat accreditation as not independently confirmed.
Relevant lines: HRT (hormone pellets, hormone injections, oral bioidentical hormones, topical creams), sexual wellness, dermatology & aesthetics, hair & scalp, anesthetics, and weight management — including sublingual semaglutide (plus naltrexone, bupropion/naltrexone, phentermine/topiramate) [2].
Per the FDA 503B list, the last inspection is logged with an action status of “Regulatory Meeting Held” (2026-01-08) [1]. We found no FDA warning letter or untitled letter for Carie Boyd’s in public sources. (A third-party directory reports a Form 483 around July 2025; we could not locate the FDA primary document, so we don’t assert it.) A regulatory meeting is a step FDA uses to discuss corrections, not a finding of violation. Dated to our review; status can change.
A well-established, broad-menu dual 503A/503B compounder that fits the consumer HRT/aesthetics/weight-loss audience, with nationwide shipping. No FDA warning letter on record as of our check; accreditation isn’t independently confirmable, which is the main gap versus a PCAB-verified operator like Empower.